Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer

@article{Borazanci2014NabpaclitaxelAG,
  title={Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer},
  author={E. Borazanci and D. V. Von Hoff},
  journal={Expert Review of Gastroenterology & Hepatology},
  year={2014},
  volume={8},
  pages={739 - 747}
}
Adenocarcinoma of the pancreas or pancreatic cancer as we will refer to it here, is a cancer of poor prognosis with a high mortality, particularly in the advanced or metastatic setting. Until 2011 and the Phase III results of FOLFIRINOX, standard treatment options were limited to gemcitabine. Combination therapy had shown either a lack of or very limited improvement versus monotherapy with gemcitabine. With the positive results of the MPACT study in 2013 showing improved survival with nab… Expand
28 Citations
Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis
Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?
...
1
2
3
...

References

SHOWING 1-10 OF 52 REFERENCES
Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Combinational therapy: new hope for pancreatic cancer?
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
...
1
2
3
4
5
...